Celiac disease is a digestive illness that causes the body to have difficulty absorbing nutrients such as lipids, calcium, iron, and folate. It is a chronic autoimmune illness that affects genetically susceptible individuals and causes damage to the small intestine when gluten is consumed. It is believed that one in every 100 individuals worldwide is affected by this disease, although only around 30% are adequately diagnosed. Additionally, rising technical developments and modernization in the healthcare sector, as well as rising R&D activities, will generate new chances for the celiac disease treatment market. According to OMR Research, the market is expected to grow at a CAGR of 8.5% during the forecast period (2023-2029). However, the limited availability of treatment options available in the market, the lack of a specific drug for the treatment of the disease, and the fact that the majority of celiac disease cases remain undiagnosed or misdiagnosed are among the major factors that will restrain market growth and further challenge the growth of the celiac disease treatment market during the forecast period.
Segments of the Market
The global celiac disease market can be divided based on treatment type, diagnostic type, and end-user. Based on treatment type, the market is subdivided into vitamins and dietary (gluten-free) supplements, steroids, immunosuppressive drugs, and therapeutic vaccines. Based on diagnostic type, the market is subdivided into serologic tests (point-of-care testing and laboratory testing), genetic testing, small-bowel biopsy, and other (endoscopy). Further, based on end-user, the market is subdivided into hospitals, diagnostics centers, and research institutes.
Recent Developments
Companies such as Abbott Laboratories, AbbVie Inc., ADMA Biologics, Inc., BioLineRX Ltd., Boston Scientific Corp., Bristol-Myers Squibb Co., Amgen Inc., Bayer AG, Bio Rad Laboratories, Inc., Calypso Biotech SA, Janssen Pharmaceuticals, Inc., ChemoCentryx, Inc., Eli Lilly and Co., GlaxoSmithKline plc, ImmunogenX Inc., and others are assisting in the market’s growth through various mergers, acquisitions, and new research and development activities. Some of the recent development in the market include:
• In May 2022, Clinical Enterprise, Inc., d/b/a empowerDX, announced the release of a groundbreaking at-home Celiac Risk Gene Test. With the founding and sponsorship of the Celiac Disease Foundation, empowerDX is in a unique position to assist a vast group of Americans suffering from painful physical and emotional discomfort with no obvious solutions.
• In September 2022, Clinical Enterprise, Inc., doing business as empowerDX, a provider of the at-home Celiac Risk Gene Test, said that NIMA Partners, the company behind the Gluten Sensor and Gluten Capsules for the detection of gluten in food particles, had partnered with the company. This collaboration exemplifies the empowerDX concept, which seeks to raise awareness and educate people about diseases that are frequently misdiagnosed or underdiagnosed.
• In March 2022, in order to expand access to care and promote research to improve outcomes for kids, Stanford Children's Health opened its new Center for Pediatric Inflammatory Bowel Disease (IBD) and Celiac Disease. This was made possible by a $70 million contribution from an unidentified donor. To get the greatest results and maintain disease management in children with IBD and celiac disease, comprehensive and committed treatment is required. A world-class program for cutting-edge clinical treatment will be developed at the new center by bringing together experienced physicians, researchers, nurses who specialize in IBD and celiac disease, dietitians, psychologists, and social workers.
• In June 2022, Everlywell announced the extension of its nutritional health category to incorporate even more digestive health solutions, such as the introduction of at-home collection tests for celiac disease and food allergies, as well as virtual and follow-up treatment. These new tests, developed and validated by leading third-party labs, complement Everlywell's Nutritional Health category of products, which already includes validated lab tests for food sensitivity, metabolism, common vitamin deficiencies, and the company's recently launched line of vitamins and supplements.
Conclusion
The increasing penetration of medicinal items in developing economies is a critical element driving market expansion. Moreover, increased diabetes rates, favorable government policies across the Western world, an increase in the number of clinical studies for medications against celiac disease, and other factors drive market expansion. Besides this, rising consumption of high-protein foods, which increases gluten consumption and leads to celiac disease, rising change in restaurant trends that offer ready-to-eat packaged foods, junk food and beverage addiction, and changing lifestyle, are all major factors driving the celiac disease treatment market.